Chembio Diagnostics (NASDAQ:CEMI) will post its quarterly earnings results after the market closes on Thursday, November 8th. Analysts expect Chembio Diagnostics to post earnings of ($0.15) per share for the quarter.
Chembio Diagnostics (NASDAQ:CEMI) last released its quarterly earnings results on Wednesday, August 8th. The company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.05). The business had revenue of $8.72 million for the quarter, compared to the consensus estimate of $6.94 million. Chembio Diagnostics had a negative net margin of 16.54% and a negative return on equity of 26.91%. On average, analysts expect Chembio Diagnostics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
CEMI traded down $0.85 during midday trading on Thursday, reaching $7.37. 56,008 shares of the company’s stock traded hands, compared to its average volume of 29,076. The firm has a market capitalization of $121.18 million, a price-to-earnings ratio of -14.19 and a beta of 1.21. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.53 and a quick ratio of 2.58. Chembio Diagnostics has a 52 week low of $5.90 and a 52 week high of $11.55.
Chembio Diagnostics Company Profile
Chembio Diagnostics, Inc, together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or monitor diseases. It offers tests for HIV and Syphilis, and Zika virus. The company also develops tests for malaria, Dengue virus, chikungunya virus, Ebola, Lassa, Marburg, leptospirosis, Rickettsia typhi, Burkholderia pseudomallei, and Orientia tsutsugamushi.
Featured Story: Asset Allocation
Receive News & Ratings for Chembio Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chembio Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.